APIM Therapeutics is focused on developing innovative cancer treatments through its lead drug candidate, ATX-101, which targets a unique therapeutic intervention point involving the Proliferating Cell Nuclear Antigen (PCNA). PCNA is a crucial scaffold protein that plays a significant role in DNA replication, repair, and various cellular processes, including stress responses. ATX-101 functions by inhibiting the interactions between PCNA and proteins that contain the APIM motif, which are involved in cellular defense mechanisms during stress conditions, such as those induced by cancer therapies. This mechanism allows ATX-101 to disrupt PCNA's scaffold functions, leading to reduced cancer cell survival and enhanced efficacy of multiple anti-cancer drugs.

The company is advancing a pipeline of peptide drugs that leverage this mechanism to address various cancer types, including ovarian cancer and sarcoma. Current clinical studies, including a phase Ib trial in combination with platinum-based chemotherapy for ovarian cancer and a phase II study in sarcoma, have shown promising results, including a favorable safety profile and disease stabilization in patients with advanced tumors. By targeting the PCNA-APIM interaction, APIM Therapeutics aims to develop both single-agent and combination therapies that can effectively meet significant unmet medical needs in oncology.

Norway

APIM Therapeutics is a venture capital financed Norwegian biotech company focusing on the development of novel treatments in the fields of oncology and inflammation. Our lead drug, ATX-101, is a first-in-class peptide drug candidate targeting a novel therapeutic intervention point involved in cellular stress defense mechanisms. ATX-101 is currently being tested in a phase I study in patients with advanced solid tumors.

APIM Therapeutics

Company Details